FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113429621> ?p ?o ?g. }

• W2113429621 endingPage "106" @default.
• W2113429621 startingPage "99" @default.
• W2113429621 abstract "Carcinoembryonic antigen (CEA), an oncofetal glycoprotein overexpressed in most gastrointestinal and lung cancers, is a candidate molecule for cancer immunotherapy. Recently, a CEA-derived 9-mer peptide, CEA652 (TYACFVSNL), has been identified as the epitope of cytotoxic T lymphocytes restricted with human leukocyte antigen (HLA)-A24, which is present in 60% of the Japanese population and in some Caucasians. The authors performed a clinical study of a vaccine using autologous dendritic cells (DCs) pulsed with CEA652 and adjuvant cytokines, natural human interferon alpha (nhuIFN-alpha), and natural human tumor necrosis factor alpha (nhuTNF-alpha), for the treatment of patients with CEA-expressing advanced metastatic malignancies. Ten HLA-A24 patients with advanced digestive tract or lung cancer were enrolled in the study to assess toxicity, tolerability and immune responses to the vaccine. DCs were generated from plastic adherent monocytes of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells (PBMCs) in the presence of granulocyte/macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4). Generated DCs showing an immature phenotype were loaded with CEA652 and injected into patients intradermally and subcutaneously with 50% of the dose administered by each route every 2 weeks for a total of ten vaccinations. The total dose of administered DCs ranged from 2.7x10(7)cells to 1.6x10(8)cells. Adjuvant cytokines, i.e., 1x10(6) U/body of nhuIFN-alpha and nhuTNF-alpha, were administered to patients twice a week during the vaccination period. No severe toxicity directly attributable to the treatment was observed, and the vaccine was well tolerated. In the delayed-type hypersensitivity (DTH) skin test, two patients showed a positive skin response to peptide-pulsed DCs after vaccination, although none of the patients tested positive prior to vaccination. In the two patients who showed a positive skin response disease remained stable for 6 and 9 months respectively. These results suggest that active immunization using DCs pulsed with CEA652 peptide in combination with the administration of adjuvant cytokines is a safe and feasible treatment procedure." @default.
• W2113429621 created "2016-06-24" @default.
• W2113429621 creator A5000738181 @default.
• W2113429621 creator A5007564314 @default.
• W2113429621 creator A5011354968 @default.
• W2113429621 creator A5015944762 @default.
• W2113429621 creator A5017077609 @default.
• W2113429621 creator A5020249052 @default.
• W2113429621 creator A5022185067 @default.
• W2113429621 creator A5032180784 @default.
• W2113429621 creator A5036773654 @default.
• W2113429621 creator A5049510355 @default.
• W2113429621 creator A5050020581 @default.
• W2113429621 creator A5073794966 @default.
• W2113429621 creator A5082265559 @default.
• W2113429621 creator A5084368591 @default.
• W2113429621 creator A5086587675 @default.
• W2113429621 date "2002-04-01" @default.
• W2113429621 modified "2023-09-26" @default.
• W2113429621 title "Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen" @default.
• W2113429621 doi "https://doi.org/10.1007/s00262-001-0257-z" @default.
• W2113429621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11904734" @default.
• W2113429621 hasPublicationYear "2002" @default.
• W2113429621 type Work @default.
• W2113429621 sameAs 2113429621 @default.
• W2113429621 citedByCount "73" @default.
• W2113429621 countsByYear W21134296212013 @default.
• W2113429621 countsByYear W21134296212014 @default.
• W2113429621 countsByYear W21134296212015 @default.
• W2113429621 countsByYear W21134296212016 @default.
• W2113429621 countsByYear W21134296212017 @default.
• W2113429621 countsByYear W21134296212018 @default.
• W2113429621 countsByYear W21134296212020 @default.
• W2113429621 countsByYear W21134296212021 @default.
• W2113429621 countsByYear W21134296212022 @default.
• W2113429621 countsByYear W21134296212023 @default.
• W2113429621 crossrefType "journal-article" @default.
• W2113429621 hasAuthorship W2113429621A5000738181 @default.
• W2113429621 hasAuthorship W2113429621A5007564314 @default.
• W2113429621 hasAuthorship W2113429621A5011354968 @default.
• W2113429621 hasAuthorship W2113429621A5015944762 @default.
• W2113429621 hasAuthorship W2113429621A5017077609 @default.
• W2113429621 hasAuthorship W2113429621A5020249052 @default.
• W2113429621 hasAuthorship W2113429621A5022185067 @default.
• W2113429621 hasAuthorship W2113429621A5032180784 @default.
• W2113429621 hasAuthorship W2113429621A5036773654 @default.
• W2113429621 hasAuthorship W2113429621A5049510355 @default.
• W2113429621 hasAuthorship W2113429621A5050020581 @default.
• W2113429621 hasAuthorship W2113429621A5073794966 @default.
• W2113429621 hasAuthorship W2113429621A5082265559 @default.
• W2113429621 hasAuthorship W2113429621A5084368591 @default.
• W2113429621 hasAuthorship W2113429621A5086587675 @default.
• W2113429621 hasBestOaLocation W21134296211 @default.
• W2113429621 hasConcept C121608353 @default.
• W2113429621 hasConcept C126322002 @default.
• W2113429621 hasConcept C137061746 @default.
• W2113429621 hasConcept C147483822 @default.
• W2113429621 hasConcept C154317977 @default.
• W2113429621 hasConcept C202751555 @default.
• W2113429621 hasConcept C203014093 @default.
• W2113429621 hasConcept C2776090121 @default.
• W2113429621 hasConcept C2777387746 @default.
• W2113429621 hasConcept C2777701055 @default.
• W2113429621 hasConcept C2777863537 @default.
• W2113429621 hasConcept C2779053233 @default.
• W2113429621 hasConcept C55493867 @default.
• W2113429621 hasConcept C71924100 @default.
• W2113429621 hasConcept C86803240 @default.
• W2113429621 hasConcept C8891405 @default.
• W2113429621 hasConceptScore W2113429621C121608353 @default.
• W2113429621 hasConceptScore W2113429621C126322002 @default.
• W2113429621 hasConceptScore W2113429621C137061746 @default.
• W2113429621 hasConceptScore W2113429621C147483822 @default.
• W2113429621 hasConceptScore W2113429621C154317977 @default.
• W2113429621 hasConceptScore W2113429621C202751555 @default.
• W2113429621 hasConceptScore W2113429621C203014093 @default.
• W2113429621 hasConceptScore W2113429621C2776090121 @default.
• W2113429621 hasConceptScore W2113429621C2777387746 @default.
• W2113429621 hasConceptScore W2113429621C2777701055 @default.
• W2113429621 hasConceptScore W2113429621C2777863537 @default.
• W2113429621 hasConceptScore W2113429621C2779053233 @default.
• W2113429621 hasConceptScore W2113429621C55493867 @default.
• W2113429621 hasConceptScore W2113429621C71924100 @default.
• W2113429621 hasConceptScore W2113429621C86803240 @default.
• W2113429621 hasConceptScore W2113429621C8891405 @default.
• W2113429621 hasIssue "2" @default.
• W2113429621 hasLocation W21134296211 @default.
• W2113429621 hasLocation W21134296212 @default.
• W2113429621 hasOpenAccess W2113429621 @default.
• W2113429621 hasPrimaryLocation W21134296211 @default.
• W2113429621 hasRelatedWork W1988182648 @default.
• W2113429621 hasRelatedWork W1993025569 @default.
• W2113429621 hasRelatedWork W2087047282 @default.
• W2113429621 hasRelatedWork W2166157026 @default.
• W2113429621 hasRelatedWork W2166919567 @default.
• W2113429621 hasRelatedWork W2220102944 @default.
• W2113429621 hasRelatedWork W3109192410 @default.
• W2113429621 hasRelatedWork W4286856427 @default.

• next